Literature DB >> 1314767

Effect of synthetic protease inhibitors on superoxide (O2-), hydrogen peroxide (H2O2) and hydroxyl radical production by human polymorphonuclear leukocytes.

K Tamura1, T Manabe, K Imanishi, A Nonaka, N Asano, K Yamaki, T Tobe.   

Abstract

The effects of clinically used protease inhibitors (aprotinin, nafamostat mesilate, gabexate mesilate) on the production of oxygen-derived free radicals (O2-, H2O2, .OH) by human polymorphonuclear leukocytes were examined. Nafamostat mesilate and gabexate mesilate markedly and dose-dependently inhibited zymosan-stimulated O2- production by human polymorphonuclear leukocytes. However, aprotinin had a slight scavenging effect on O2- produced by the xanthine-xanthine oxidase system. All the protease inhibitors inhibited H2O2 production, but had no significant scavenging effect on H2O2. Nafamostat mesilate and gabexate mesilate slightly inhibited .OH production. These results indicate that the synthetic protease inhibitors nafamostat mesilate and gabexate mesilate inhibit the production of various activated oxygen radicals by human polymorphonuclear leukocytes, and the differences in their inhibitory effects suggest that each synthetic protease inhibitor is specific for a particular oxygen-derived free radical.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1314767

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  3 in total

1.  Serine protease inhibitors block priming of monocytes for enhanced release of superoxide.

Authors:  P Megyeri; K M Pabst; M J Pabst
Journal:  Immunology       Date:  1995-12       Impact factor: 7.397

2.  Nafamostat Mesilate Inhibits TNF-α-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production.

Authors:  Min-Woong Kang; Hee-Jung Song; Shin Kwang Kang; Yonghwan Kim; Saet-Byel Jung; Sungju Jee; Jae Young Moon; Kwang-Sun Suh; Sang Do Lee; Byeong Hwa Jeon; Cuk-Seong Kim
Journal:  Korean J Physiol Pharmacol       Date:  2015-04-30       Impact factor: 2.016

3.  Nafamostat mesilate: can it be used as a conduit preserving agent in coronary artery bypass surgery?

Authors:  Yoo Sang Yoon; Hyunkong Oh; Yonghwan Kim; Seung Pyung Lim; Cuk-Seong Kim; Min-Woong Kang
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2013-12-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.